key: cord-0264732-n5p9e0ob authors: Havervall, S.; Marking, U.; Gordon, M.; Ng, H.; Greilert-Norin, N.; Lindbo, S.; Blom, K.; Nilsson, P.; Phillipson, M.; Klingstrom, J.; Mangsbo, S.; Aberg, M.; Hober, S.; Thalin, C. title: Neutralization of VOCs including Delta one year post COVID-19 or vaccine date: 2021-08-12 journal: nan DOI: 10.1101/2021.08.12.21261951 sha: 0898c80d99eeaa09bbda7e378ec845388385c855 doc_id: 264732 cord_uid: n5p9e0ob Background: SARS-CoV-2 variants, such as Alpha, Beta, Gamma and Delta, are raising concern about the efficiency of neutralizing antibodies (NAb) induced by wild-type infection or vaccines based on the wild-type spike. Methods: We determined IgG and NAb against SARS-CoV-2 variants one year following mild wild-type infection (n=104) and two-dose regimens with BNT162b2 (BNT/BNT) (n=67), ChAdOx1 (ChAd/ChAd) (n=82), or heterologous ChAdOx1 followed by BNT162b2 (ChAd/BNT) (n=116). Findings: Wild type spike IgG and NAb remained detectable in 80% (83/104) of unvaccinated participants one year post mild infection. The neutralizing capacity was similar against wild type (reference), Alpha (0.95 (0.92-0.98) and Delta 1.03 (0.95-1.11) but significantly reduced against Beta (0.54 (0.48-0.60)) and Gamma 0.51 (0.44-0.61). Similarly, BNT/BNT and ChAd/ChAd elicited sustained capacity against Alpha and Delta (1.01 (0.78-1.31) and 1.03 (0.95-1.11)) and (0.96 (0.84-1.09) and 0.82 (0.61-1.10) respectively), with reduced capacity against Beta (0.67 (0.50-0.88) and 0.53 (0.40-0.71)) and Gamma (0.12 (0.06-0.27) and 0.54 (0.37-0.80)). A similar trend was found following ChAd/BNT (0.74 (0.66-0.83) and 0.70 (0.50-0.97) against Alpha and Delta and 0.29 (0.20-0.42) and 0.13 (0.08-0.20) against Beta and Gamma). Interpretation: Persistent neutralization of the wide-spread Alpha and Delta variants one year after wild-type infection may aid vaccine policy makers in low-resource settings when prioritizing vaccine supply. The reduced capacity of neutralizing Beta and Gamma strains, but not the Alpha and Delta strains following both infection and three different vaccine regimens argues for caution against Beta and Gamma-exclusive mutations in the efforts to optimize next generation SARS-CoV-2 vaccines. Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section year after wild-type infection may aid vaccine policy makers in low-resource settings when 59 prioritizing vaccine supply. The reduced capacity of neutralizing Beta and Gamma strains, 60 but not the Alpha and Delta strains following both infection and three different vaccine 61 regimens argues for caution against Beta and Gamma-exclusive mutations in the efforts to 62 optimize next generation SARS-CoV-2 vaccines. 63 64 Funding: A full list of funding bodies that contributed to this study can be found in the 65 Increasing data support that neutralizing antibodies following SARS-CoV-2 infection provide 70 a durable protection against reinfection (1-7), and vaccines have been shown effective in 71 constraining hospitalization and deaths associated with SARS-CoV-2 infection (8) (9) (10) (11) . 72 However, emerging SARS-CoV-2 variants are raising concerns. Viral variants of concern 73 (VOC) with increased transmissibility, such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) 74 and B.1.617.2 (Delta), entail spike protein mutations conferring a fitness advantage affecting 75 its biology, infectivity, transmissibility, and antigenicity ( Figure 1 ). Spike alterations may 76 enable immune escape, specially voiced when it comes to the B.1.351 (Beta) and P1 77 (Gamma) VOC. Both display three mutations in the RBD region and particularly related to the 78 E484K mutation, which has been shown to reduce antibody binding and neutralization (12). 79 Assessing the efficiency of humoral immunity following wild-type infection and current 80 vaccines against these globally spreading VOCs is important, both for understanding SARS-81 CoV-2 virulence and for the optimization of next generation SARS-CoV-2 vaccines (13-21). 82 Using a high-throughput spike-specific IgG and pseudoneutralization assay, we determined 83 the SARS-CoV-2 IgG antibody levels and neutralization capacity against the wild-type virus 84 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 This sub study included one group with all study participants that were confirmed SARS-105 CoV-2 Spike IgG positive by both assays at study inclusion, who attended all follow-ups and 106 who were not yet vaccinated by the 12-month follow-up. All participants reported mild 107 COVID-19 symptoms, and none were hospitalized. Blood samples were also obtained from 108 three groups of vaccinated individuals: all participants who received two doses of BNT162b2 109 vaccine (BNT x 2; median dose interval 21 days (IQR 21-21), two doses of ChAdOx1 nCoV-110 19 vaccine (ChAd x 2; median dose interval 81.5 days (IQR 77-84)) or a prime dose of 111 ChAdOx1 nCoV-19 vaccine and booster dose with BNT162b2 vaccine (ChAd + BNT; median 112 dose interval 90 days (IQR 86-94)). Blood samples were collected 30-55 days following the 113 BNT x 2 regimens, and 14-22 days following regimens with ChAd priming. The study was 114 approved by the Swedish Ethical Review Authority (dnr 2020-01653), and written informed 115 consent was obtained from all study participants. 116 117 We used mixed effect modelling with subject id as random effect where the outcome during 119 modelling was converted using the log2-function. Interaction between strain and timespans 120 was tested in two subsequent steps, baseline vs any other follow-up, and within the follow-121 ups. The models were compared using ANOVA. Analyses were performed in R version 4.1.0 122 with nlme-package (v. 3.1.152). The estimates were compared using the contrast-package 123 (v. 0.22). Each model was adjusted for age and sex. Correlation analysis was performed 124 using Spearman. 125 126 The funders had no role in the design and conduct of the study; collection, management, 128 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; 129 and decision to submit the manuscript for publication. 130 131 A total of 104 study participants who were confirmed spike IgG positive at study inclusion 133 and attended all four-month follow-ups remained unvaccinated at the 12-month follow-up 134 (median age 42 (IQR 31.75-51.25), 88% female). In line with prior reports (3, 4, 25) the levels 135 of both spike binding IgG and neutralizing antibodies (NAb) against the SARS-CoV-2 wild-136 type strain declined over the first few months, but thereafter remained stable, (Fig 2 A-B) , 137 with similar trends for all SARS-CoV-2 VOCs (Table S1 ). High spike IgG and NAb levels at perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in wild-type strain, and that this capacity is maintained over time, implying a robust immunity 173 also against these now globally spreading strains. Notably, neutralizing capacity was, 174 however, significantly reduced against the B.1.351 (Beta) and P.1 (Gamma) strains. 175 The two vaccines used in the studied regimens are both based on the wild-type SARS-CoV-2 176 spike protein. We found that these three vaccine regimens elicited a similar response as 177 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.12.21261951 doi: medRxiv preprint infection with the wild-type strain. Although the virulence of a certain VOC as well as the level 178 of evoked immune protection is dependent on a multitude of features, it is highly influenced 179 by the interaction between the viral spike protein and the host ACE2 receptor. A VOC with 180 higher affinity to ACE2 potentially needs fewer virions to be infective. Further, escape 181 mutants able to evade the immune system might appear as the immunity develops globally. in position 417 (in P.1 (Gamma)) appears to give a negative effect for the BNT vaccine 189 (Figure 1 and 3) . The higher transmissibility of lineage B.1.617.2 (Delta) does not seem to be 190 based on a lower antibody protection due to the two mutations in RBD alone. However, a 191 higher rate of proliferation has been reported (27) for this VOC. The major concern regarding 192 this VOC does not seem to stem from immune escape but could instead be due to other 193 improved fitness characteristics. 194 So far, the E484 mutation has been reported to affect antibody binding and neutralization 195 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 12, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology. 2021;19 (7) perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.12.21261951 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.12.21261951 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.12.21261951 doi: medRxiv preprint SARS-CoV-2 254 infection induces long-lived bone marrow plasma cells in humans Safety and 256 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 257 randomised controlled trials in Brazil, South Africa, and the UK Safety and 259 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Vaccine 262 effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in 263 residents of long-term care facilities in England (VIVALDI): a prospective cohort study. The Lancet 264 Infectious Diseases BNT162b2 mRNA 266 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect 270 recognition by polyclonal human plasma antibodies Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel) Increased resistance of 276 SARS-CoV-2 variant P.1 to antibody neutralization Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Vaccine against the B.1.1.7 and B.1.351 Variants CoV2373 Covid-19 Vaccine against the B.1.351 Variant ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of 288 Medicine SARS-CoV-2 290 Variants and Vaccines CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden Symptoms 295 and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. 296 JAMA Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex 299 serological COVID-19 assay Longitudinal 301 observation and decline of neutralizing antibody responses in the three months following SARS-CoV-302 2 infection in humans Acknowledgements 0.82 (0.61 -1.10) Regression output for strain type neutralization. Estimates are multiplicative, i.e. 0.5 corresponds to a 50% reduction in antibody response. Each group is a quantile regression model for the median with mixed effect.